<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 15 Apr 2021 07:21:18 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>药物制剂元素杂质控制该如何做？</title><link>https://mp.weixin.qq.com/s/TvvXScs5hhgxv5yzXQvPtg</link><description></description><content:encoded><![CDATA[药物制剂元素杂质控制该如何做？]]></content:encoded><pubDate>Wed, 14 Apr 2021 20:26:51 +0800</pubDate></item><item><title>抗体药物偶联物的平均偶联率分析方法</title><link>https://mp.weixin.qq.com/s/Af8PY7q0R18-UU1rT8r1gA</link><description></description><content:encoded><![CDATA[抗体药物偶联物的平均偶联率分析方法]]></content:encoded><pubDate>Wed, 14 Apr 2021 20:26:51 +0800</pubDate></item><item><title>信达生物2020年业绩推介PPT</title><link>https://mp.weixin.qq.com/s/2-G-vQV9J3RLJDU2ApF8ZA</link><description></description><content:encoded><![CDATA[信达生物2020年业绩推介PPT]]></content:encoded><pubDate>Wed, 14 Apr 2021 20:26:51 +0800</pubDate></item><item><title>【上海】2021抗体类药物申报中的质量分析及结构表征技术研修班</title><link>https://mp.weixin.qq.com/s/JA6sPhVBckmYowLhsd1tLw</link><description></description><content:encoded><![CDATA[【上海】2021抗体类药物申报中的质量分析及结构表征技术研修班]]></content:encoded><pubDate>Wed, 14 Apr 2021 20:26:51 +0800</pubDate></item><item><title>ADC药物蓄势待发，积跬致远，琢玉成器</title><link>https://mp.weixin.qq.com/s/Km-dY1BJOMxg9yfpDaH8SQ</link><description></description><content:encoded><![CDATA[ADC药物蓄势待发，积跬致远，琢玉成器]]></content:encoded><pubDate>Tue, 13 Apr 2021 19:29:56 +0800</pubDate></item><item><title>扩展、改剂型、改规格；CDE征求《儿童用化学药品改良型新药临床试验技术指导原则（征求意见稿）》意见</title><link>https://mp.weixin.qq.com/s/LzWOLl5D5kAu_d6-VuQH_w</link><description></description><content:encoded><![CDATA[扩展、改剂型、改规格；CDE征求《儿童用化学药品改良型新药临床试验技术指导原则（征求意见稿）》意见]]></content:encoded><pubDate>Tue, 13 Apr 2021 19:29:56 +0800</pubDate></item><item><title>速递 II CDE发布4品种BE指导原则征求意见稿（盐酸乐卡地平片、枸橼酸西地那非口崩片、熊去氧胆酸胶囊、氯化钾缓释片）</title><link>https://mp.weixin.qq.com/s/KKhBr-x0-8lFADxvUungJg</link><description></description><content:encoded><![CDATA[速递 II CDE发布4品种BE指导原则征求意见稿（盐酸乐卡地平片、枸橼酸西地那非口崩片、熊去氧胆酸胶囊、氯化钾缓释片）]]></content:encoded><pubDate>Tue, 13 Apr 2021 19:29:56 +0800</pubDate></item><item><title>创新单抗药物申报临床试验病毒安全性相关监管指南调研与技术考量</title><link>https://mp.weixin.qq.com/s/LPB8YEuJQTLMoGyRnnqGvg</link><description></description><content:encoded><![CDATA[创新单抗药物申报临床试验病毒安全性相关监管指南调研与技术考量]]></content:encoded><pubDate>Tue, 13 Apr 2021 06:33:38 +0800</pubDate></item><item><title>原料药中杂质分析技巧</title><link>https://mp.weixin.qq.com/s/QZ_NnjLxuEqxHZ3lSXyY8A</link><description></description><content:encoded><![CDATA[原料药中杂质分析技巧]]></content:encoded><pubDate>Tue, 13 Apr 2021 06:33:38 +0800</pubDate></item><item><title>2021年CAR-T行业研究报告</title><link>https://mp.weixin.qq.com/s/QhjZX3tLTN_dNnYaMjuI7Q</link><description></description><content:encoded><![CDATA[2021年CAR-T行业研究报告]]></content:encoded><pubDate>Tue, 13 Apr 2021 06:33:38 +0800</pubDate></item><item><title>非小细胞肺癌罕见靶点靶向治疗最新研究进展</title><link>https://mp.weixin.qq.com/s/YoPktf2hWF58DgLSGmvA5w</link><description></description><content:encoded><![CDATA[非小细胞肺癌罕见靶点靶向治疗最新研究进展]]></content:encoded><pubDate>Mon, 12 Apr 2021 07:15:55 +0800</pubDate></item><item><title>药物制剂工艺研究和工艺验证</title><link>https://mp.weixin.qq.com/s/V0YdHphEBpyMbbGgN1neJQ</link><description></description><content:encoded><![CDATA[药物制剂工艺研究和工艺验证]]></content:encoded><pubDate>Mon, 12 Apr 2021 07:15:55 +0800</pubDate></item><item><title>药物的多晶型与药物制剂的开发</title><link>https://mp.weixin.qq.com/s/_Cr4xAjLAUZlbfFpW5F5lA</link><description></description><content:encoded><![CDATA[药物的多晶型与药物制剂的开发]]></content:encoded><pubDate>Mon, 12 Apr 2021 07:15:55 +0800</pubDate></item><item><title>替雷利珠单抗注射液 申请上市技术审评报告</title><link>https://mp.weixin.qq.com/s/Yd3-3pB9H8rZmap28z7Tzw</link><description></description><content:encoded><![CDATA[替雷利珠单抗注射液 申请上市技术审评报告]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:17 +0800</pubDate></item><item><title>图说：看干细胞如何保护人体八大系统</title><link>https://mp.weixin.qq.com/s/5y5zCkQDkr3YZldJv37Xhg</link><description></description><content:encoded><![CDATA[图说：看干细胞如何保护人体八大系统]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:17 +0800</pubDate></item><item><title>生物药研发注册申报及质量研究</title><link>https://mp.weixin.qq.com/s/c4kvc6FFJkjJXP3AsCXkEA</link><description></description><content:encoded><![CDATA[生物药研发注册申报及质量研究]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:17 +0800</pubDate></item><item><title>乳腺癌靶向药物的研究及临床应用新进展</title><link>https://mp.weixin.qq.com/s/jrVzkltbPIdIqF6kOFQf2A</link><description></description><content:encoded><![CDATA[乳腺癌靶向药物的研究及临床应用新进展]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>CDK4/6靶向药：七大问题，范蕾教授为您一次解答！</title><link>https://mp.weixin.qq.com/s/x6oTk2Jbfxd-JyjW8zid0w</link><description></description><content:encoded><![CDATA[CDK4/6靶向药：七大问题，范蕾教授为您一次解答！]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>图解｜一图读懂《化妆品分类规则和分类目录》</title><link>https://mp.weixin.qq.com/s/L1d26urhY1EkDl3sOdWUPA</link><description></description><content:encoded><![CDATA[图解｜一图读懂《化妆品分类规则和分类目录》]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>CAR-T新药跑步上市，国内研发竞赛如火如荼</title><link>https://mp.weixin.qq.com/s/l-XT9zjm739GSIXUlJ7AzQ</link><description></description><content:encoded><![CDATA[CAR-T新药跑步上市，国内研发竞赛如火如荼]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item></channel></rss>